Vertex’s Kalydeco gets FDA aapproval for children with cystic fibrosis
The drug is approved for children with CF who have one of ten mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (G551D, G1244E, G1349D, G178R, G551S,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.